Wedbush Weighs in on Apellis Pharmaceuticals, Inc.’s FY2025 Earnings (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities research analysts at Wedbush dropped their FY2025 earnings per share estimates for Apellis Pharmaceuticals in a research report issued on Wednesday, April 17th. Wedbush analyst L. Chico now anticipates that the company will post earnings of $2.23 per share for the year, down from their prior forecast of $2.24. Wedbush currently has a “Neutral” rating and a $57.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.33) per share.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.73). The business had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The firm’s revenue for the quarter was up 545.9% on a year-over-year basis. During the same period in the previous year, the company posted ($1.50) earnings per share.

APLS has been the subject of several other research reports. Jefferies Financial Group upgraded Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price objective for the company from $68.00 to $80.00 in a report on Monday, February 5th. The Goldman Sachs Group lifted their target price on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, January 9th. UBS Group lifted their target price on Apellis Pharmaceuticals from $87.00 to $89.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Robert W. Baird reaffirmed an “outperform” rating and set a $81.00 target price on shares of Apellis Pharmaceuticals in a research report on Tuesday, February 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $92.00 target price on shares of Apellis Pharmaceuticals in a research report on Monday, April 15th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $77.93.

Apellis Pharmaceuticals Trading Up 0.0 %

NASDAQ APLS opened at $47.53 on Thursday. The company has a market cap of $5.73 billion, a price-to-earnings ratio of -10.61 and a beta of 0.88. Apellis Pharmaceuticals has a 52 week low of $19.83 and a 52 week high of $94.75. The business has a 50 day moving average price of $59.71 and a 200-day moving average price of $57.04. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48.

Institutional Trading of Apellis Pharmaceuticals

Several hedge funds have recently bought and sold shares of APLS. Price T Rowe Associates Inc. MD grew its holdings in Apellis Pharmaceuticals by 66.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,590,040 shares of the company’s stock valued at $302,760,000 after purchasing an additional 1,840,498 shares during the period. Jennison Associates LLC boosted its stake in shares of Apellis Pharmaceuticals by 79.8% in the third quarter. Jennison Associates LLC now owns 3,542,209 shares of the company’s stock worth $134,746,000 after acquiring an additional 1,571,606 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Apellis Pharmaceuticals by 109.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock worth $128,400,000 after acquiring an additional 1,121,497 shares during the period. Norges Bank bought a new position in shares of Apellis Pharmaceuticals in the fourth quarter worth about $54,164,000. Finally, Morgan Stanley boosted its stake in shares of Apellis Pharmaceuticals by 112.6% in the third quarter. Morgan Stanley now owns 1,608,996 shares of the company’s stock worth $61,206,000 after acquiring an additional 852,331 shares during the period. Institutional investors own 96.29% of the company’s stock.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CAO James George Chopas sold 1,061 shares of Apellis Pharmaceuticals stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $65.00, for a total transaction of $68,965.00. Following the completion of the transaction, the chief accounting officer now owns 39,067 shares in the company, valued at $2,539,355. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CAO James George Chopas sold 1,061 shares of the business’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $65.00, for a total value of $68,965.00. Following the completion of the transaction, the chief accounting officer now owns 39,067 shares in the company, valued at $2,539,355. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Pascal Deschatelets sold 69,107 shares of the business’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 406,651 shares of company stock worth $25,130,257. 7.50% of the stock is owned by insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).